Online citations, reference lists, and bibliographies.
← Back to Search

Individualizing Mesothelioma Treatment: Small Steps Into A Brighter Future.

L. Garland, Raja Flores, A. Tsao
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
development of more effective therapies for mesothelioma, with an emphasis on individualizing mesothelioma treatment, thus remains of great interest. Mesothelioma is a disease that presents unique challenges but also significant opportunities for the development of personalized medicine. Its relative rarity, biologic heterogeneity, and inherent chemotherapy- and radiation-resistance continue to challenge efforts to discover and develop novel therapeutic strategies that can be validated in well powered randomized clinical trials. However, the availability of pleural tumor from diagnostic pleural biopsies and pleurectomy specimens provides a distinct opportunity for molecular/genetic studies that can yield prognostic and predictive biomarkers upon which individualized therapy can be designed. We expect current therapeutic strategies to evolve based on a number of recent, ground breaking studies as well as preclinical studies and clinical trials that are currently under way. Herein, we discuss opportunities for individualizing both local and systemic therapy, highlighting how mesothelioma treatment may progress over the course of the upcoming decade.
This paper references
10.1016/S0140-6736(08)60703-5
Chemotherapy for malignant pleural mesothelioma
N. Vogelzang (2008)
10.1093/jnci/djp061
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
10.1200/JCO.2005.14.167
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1182/blood-2008-08-173799
Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.
M. Stark (2009)
10.1158/0008-5472.CAN-09-3993
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
H. Pass (2010)
10.1158/1078-0432.CCR-07-0162
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
S. Ramalingam (2007)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/j.jtcvs.2006.06.044
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
10.1200/JCO.2010.28.15_SUPPL.E18045
ERCC1, RRM1, and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Chunxia Su (2010)
10.1200/JCO.2010.28.15_SUPPL.7042
Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma.
Anne S. Tsao (2010)
SWOG S 0509 : A phase II study of novel oral antiangiogenic agent AZD 2171 ( NSC - 732208 ) in malignant pleural mesothelioma
L Garland (2009)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1016/S1359-6349(09)71840-3
9127 The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin
Paolo Andrea Zucali (2009)
10.1200/jco.2009.27.15_suppl.7511
SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma.
L. Garland (2009)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1158/1535-7163.MCT-07-0052
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1007/S12032-010-9553-9
ERCC1 is not expressed in hepatocellular cancer: A turkish oncology group, gastrointestinal oncology subgroup study.
Chunxia Su (2011)
10.1016/j.ejcts.2010.02.012
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
T. Mineo (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar